|
1
|
Warshaw AL and Fernandez-del Castillo C:
Pancreatic carcinoma. N Engl J Med. 326:455–465. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar
|
|
3
|
Yeo TP, Hruban RH, Leach SD, et al:
Pancreatic cancer. Curr Probl Cancer. 26:176–275. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sutherland LC, Wang K and Robinson AG:
RBM5 as a putative tumor suppressor gene for lung cancer. J Thorac
Oncol. 5:294–298. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oh JJ, Razfar A, Delgado I, et al: 3p21.3
tumor suppressor gene H37/Luca15/RBM5 inhibits growth of human lung
cancer cells through cell cycle arrest and apoptosis. Cancer Res.
66:3419–3427. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heidorn SJ, Milagre C, Whittaker S, et al:
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor
progression through CRAF. Cell. 140:209–221. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Suda K, Tomizawa K and Mitsudomi T:
Biological and clinical significance of KRAS mutations in lung
cancer: an oncogenic driver that contrasts with EGFR mutation.
Cancer Metastasis Rev. 29:49–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schneider G and Schmid RM: Genetic
alterations in pancreatic carcinoma. Mol Cancer. 2:152003.
View Article : Google Scholar
|
|
9
|
Kobayashi T, Ishida J, Musashi M, et al:
p53 transactivation is involved in the antiproliferative activity
of the putative tumor suppressor RBM5. Int J Cancer. 128:304–318.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liang H, Zhang J, Shao C, et al:
Differential expression of RBM5, EGFR and KRAS mRNA and protein in
non-small cell lung cancer tissues. J Exp Clin Cancer Res.
31:362012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sobin LH and Fleming ID: TNM
Classification of Malignant Tumors. Vol 80 (5th edition). Union
Internationale Contre le Cancer and the American Joint Committee on
Cancer. 1803–1804. 1997.
|
|
12
|
Zhou X, Hao Q, Liao J, Zhang Q and Lu H:
Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal
stress. Oncogene. 2012.PubMed/NCBI
|
|
13
|
Rintala-Maki ND, Goard CA, Langdon CE, et
al: Expression of RBM5-related factors in primary breast tissue. J
Cell Biochem. 100:1440–1458. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Welling DB, Lasak JM, Akhmametyeva E,
Ghaheri B and Chang LS: cDNA microarray analysis of vestibular
schwannomas. Otol Neurotol. 23:736–748. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim YS, Hwan JD, Bae S, Bae DH and Shick
WA: Identification of differentially expressed genes using an
annealing control primer system in stage III serous ovarian
carcinoma. BMC Cancer. 10:5762010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Maarabouni MM and Williams GT: The
antiapoptotic RBM5/LUCA-15/H37 gene and its role in apoptosis and
human cancer: research update. Scientific World Journal.
6:1705–1712. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rintala-Maki ND, Abrasonis V, Burd M and
Sutherland LC: Genetic instability of RBM5/LUCA-15/H37 in MCF-7
breast carcinoma sublines may affect susceptibility to apoptosis.
Cell Biochem Funct. 22:307–313. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shao C, Zhao L, Wang K, Xu W, Zhang J and
Yang B: The tumor suppressor gene RBM5 inhibits lung adenocarcinoma
cell growth and induces apoptosis. World J Surg Oncol. 10:1602012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Oh JJ, Taschereau EO, Koegel AK, et al:
RBM5/H37 tumor suppressor, located at the lung cancer hot spot
3p21.3, alters expression of genes involved in metastasis. Lung
Cancer. 70:253–262. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang K, Ubriaco G and Sutherland LC:
RBM6-RBM5 transcription-induced chimeras are differentially
expressed in tumours. BMC Genomics. 8:3482007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kang R and Tang D: Autophagy in pancreatic
cancer pathogenesis and treatment. Am J Cancer Res. 2:383–396.
2012.PubMed/NCBI
|
|
22
|
Ying H, Kimmelman AC, Lyssiotis CA, et al:
Oncogenic Kras maintains pancreatic tumors through regulation of
anabolic glucose metabolism. Cell. 149:656–670. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rall CJ, Yan YX, Graeme-Cook F, et al:
Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma.
Pancreas. 12:10–17. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hruban RH, van Mansfeld AD, Offerhaus GJ,
et al: K-ras oncogene activation in adenocarcinoma of the human
pancreas. A study of 82 carcinomas using a combination of
mutant-enriched polymerase chain reaction analysis and
allele-specific oligonucleotide hybridization. Am J Pathol.
143:545–554. 1993.
|
|
25
|
Grunewald K, Lyons J, Frohlich A, et al:
High frequency of Ki-ras codon 12 mutations in pancreatic
adenocarcinomas. Int J Cancer. 43:1037–1041. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Garcea G, Neal CP, Pattenden CJ, Steward
WP and Berry DP: Molecular prognostic markers in pancreatic cancer:
a systematic review. Eur J Cancer. 41:2213–2236. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Castells A, Puig P, Mora J, et al: K-ras
mutations in DNA extracted from the plasma of patients with
pancreatic carcinoma: diagnostic utility and prognostic
significance. J Clin Oncol. 17:578–584. 1999.PubMed/NCBI
|
|
28
|
Finkelstein SD, Przygodzki R, Pricolo VE,
et al: K-ras-2 topographic genotyping of pancreatic adenocarcinoma.
Arch Surg. 129:367–372; discussion 372–363, 1994.
|
|
29
|
Gazdar AF, Gao B and Minna JD: Lung cancer
cell lines: Useless artifacts or invaluable tools for medical
science? Lung Cancer. 68:309–318. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Masilamani TJ, Rintala-Maki ND, Wang K and
Sutherland LC: Downregulating activated epidermal growth factor
receptor has no effect on RBM5 expression. Chin Med J (Engl).
125:2378–2381. 2012.PubMed/NCBI
|
|
31
|
Song MM, Nio Y, Dong M, et al: Comparison
of K-ras point mutations at codon 12 and p21 expression in
pancreatic cancer between Japanese and Chinese patients. J Surg
Oncol. 75:176–185. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dergham ST, Dugan MC, Kucway R, et al:
Prevalence and clinical significance of combined K-ras mutation and
p53 aberration in pancreatic adenocarcinoma. Int J Pancreatol.
21:127–143. 1997.PubMed/NCBI
|
|
33
|
Motojima K, Urano T, Nagata Y, Shiku H,
Tsunoda T and Kanematsu T: Mutations in the Kirsten-ras oncogene
are common but lack correlation with prognosis and tumor stage in
human pancreatic carcinoma. Am J Gastroenterol. 86:1784–1788.
1991.PubMed/NCBI
|
